menu
    • menu
    [{"orgOrder":0,"company":"Famar","sponsor":"Medicom Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FAMAR and Medicom Healthcare Announce The Acquisition By Medicom Of The Pharmaceutical Dossier Of BIMATOPROST","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Acquisition","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Famar","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Famar \/ Famar","highestDevelopmentStatusID":"12","companyTruncated":"Famar \/ Famar"},{"orgOrder":0,"company":"Famar","sponsor":"Active Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Active Biotech Enters into a Manufacturing Agreement with Famar Health Care Services for New Formulation of Laquinimod","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Laquinimod","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Famar","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Famar \/ Active Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Famar \/ Active Biotech"},{"orgOrder":0,"company":"Famar","sponsor":"LaviPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Collaboration Between FAMAR and Lavipharm: Joining Forces in the Production of Pharmaceutical Products","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Famar","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Famar \/ Lavipharm","highestDevelopmentStatusID":"12","companyTruncated":"Famar \/ Lavipharm"}]

    Find Clinical Drug Pipeline Developments & Deals by Famar

    Menu

    Famar

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    Key Services KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Famar

                            Greece arrow
                            CPhI Worldwide, Milan
                            Booth #5C27
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothFAMAR CDMO- From early development to commercial manufacturing.

                            Lead Product(s) : Paracetamol,Caffeine

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : LaviPharm

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            New Collaboration Between FAMAR and Lavipharm: Joining Forces in the Production of Pharmaceutical Products

                            Details : Under the collaboration, FAMAR will undertake the production of two pharmaceutical products recently added to Lavipharm’s portfolio of analgesic pharmaceutical products, Lonarid N (paracetamol) and Lonalgal (caffeine Anhydrous).

                            Brand Name : Lonarid N

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 23, 2024

                            Lead Product(s) : Paracetamol,Caffeine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : LaviPharm

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Famar

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Famar

                            Greece arrow
                            CPhI Worldwide, Milan
                            Booth #5C27
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothFAMAR CDMO- From early development to commercial manufacturing.

                            Lead Product(s) : Bimatoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Medicom Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            FAMAR and Medicom Healthcare Announce The Acquisition By Medicom Of The Pharmaceutical Dossier Of BIMATOPROST

                            Details : Under the agreement, Medicom has acquired the ownership of the pharmaceutical dossier of Zimed (bimatoprost), a preservative free eye drop solution, which is already registered in the UK and 5 EU countries with plans to commercialise the asset globally.

                            Brand Name : Zimed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 09, 2021

                            Lead Product(s) : Bimatoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Medicom Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            Famar

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Famar

                            Greece arrow
                            CPhI Worldwide, Milan
                            Booth #5C27
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothFAMAR CDMO- From early development to commercial manufacturing.

                            Lead Product(s) : Laquinimod

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Active Biotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Active Biotech Enters into a Manufacturing Agreement with Famar Health Care Services for New Formulation of La...

                            Details : Through the agreement, Active Biotech will get the material for the clinical development of the eye-drop formulation of ABR-215062 (laquinimod), which is used for the treatment of non-infectious non-anterior uveitis.

                            Brand Name : ABR-215062

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 04, 2021

                            Lead Product(s) : Laquinimod

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Active Biotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Famar

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth